

**FHS PUBLIC ACCESS**

Author manuscript

Nat Genet. Author manuscript; available in PMC 2015 May 01.

Published in final edited form as:

Nat Genet. 2014 November ; 46(11): 1233–1238. doi:10.1038/ng.3105.

Genome-wide association study identifies multiple susceptibility loci for diffuse large B-cell lymphoma*A full list of authors and affiliations appears at the end of the article.***Introductory Paragraph**

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of three new genome-wide association studies (GWAS) and one prior scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of nine promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (*EXOC2*; $P=2.33\times 10^{-21}$), rs2523607 at 6p21.33 (*HLA-B*; 2.40×10^{-10}), rs79480871 at 2p23.3 (*NCOA1*; $P=4.23\times 10^{-8}$), and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (*PVT1*; $P=9.98\times 10^{-13}$ and $P=3.63\times 10^{-11}$, respectively). These data provide substantial new evidence for genetic susceptibility to this B-cell malignancy, and point towards pathways involved in immune recognition and immune function in the pathogenesis of DLBCL.

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma (NHL)¹, has an aggressive clinical course². The risk of DLBCL is increased in individuals with a family history of NHL (odds ratio (OR)=1.4; 95% CI 1.1–2.0)³, supporting a genetic contribution. Also, relatives of DLBCL patients are at elevated risk for both DLBCL (RR=9.8, 95% CI 3.1–31) and Hodgkin lymphoma (HL, RR=2.0, 95% CI 1.05–

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence should be addressed to: James R. Cerhan, M.D., Ph.D., Mayo Clinic, 200 First Street SW, Rochester, MN 55905, Phone: 507.538.0499, Fax: 507.226.2478, cerhan.james@mayo.edu.

⁹⁴These authors contributed equally to this work.

⁹⁵These authors jointly directed this work.

AUTHORS CONTRIBUTIONS

J.R.C., S.I.B., S.S.W., A.N., A.R.B.-W., Q.L., G. Severi, M. Melbye, L.R.T., M.P.P., C.L., B.M.B., S.L.S., S.d.S., K.E.S., C.F.S., N.R. and S.J.C. organized and designed the study. J.R.C., L.C., L.B., A.H., P.M.B., E.A.H., S.L.S., G. Salles, C.F.S., N.R. and S.J.C. conducted and supervised the genotyping of samples. J.R.C., S.I.B., V.J., Z.W., M.Y., L.C., P.I.W.d.B., D.C., J.G., D. Zhi, Y.W.A., J.H., B.M., J.S., L.L., J.P., C.C.C., N.C., S.d.S., K.E.S., C.F.S., N.R. and S.J.C. contributed to the design and execution of statistical analysis. J.R.C., S.I.B., V.J., H.G., J.M., S.S.W., Z.W., M.Y., L.C., A.N., D.C., A.M., C.R.F., A.J.D.R., C.L., K.E.S., C.F.S., N.R. and S.J.C. wrote the first draft of the manuscript. J.R.C., V.J., H.G., J.M., S.S.W., L.C., A.N., L.B., A.M., A.R.B.-W., Q.L., G. Severi, M. Melbye, J.G., R.D.J., E.K., L.R.T., M.P.P., C.M.V., J.J.S., G.G.G., D.A., R.S.K., M.Z., K.A.B., A.Z.-J., T.M.H., B.K.L., A.J.N., A.D., Y.W.A., M.L., C.A.T., S.M.A., T.E.W., G.J.W., A.S.V., D. Zelenika, H.T., C.H., T.J.M., H.H., B.G., H.-O.A., P.M.B., J.R., M.T.S., E.A.H., W.C., P.H., L.M.M., R.K.S., L.F.T., K.E.N., N.B., Y.B., P. Boffetta, P. Brennan, L.F., M. Maynadie, A. Staines, T.L., S.C., A. Smith, E. Roman, W.R.D., K.O., A.Z., R.J.K., D.J.V., T.Z., Y.Z., T.R.H., A.K., J.T., M.C.S., J.C., J. Virtamo, S.W., E. Riboli, P.V., R.K., D.T., R.C.H.V., H.B., A.T., E.A., S.D.L., M.R., B.M.B., F.L., E.G., P.K., Y.Y., B.C.H.C., D.D.W., N.C., J.F.F.J., S.L.S., X.W., S.d.S., K.E.S., G. Salles, C.F.S. and N.R. conducted the epidemiological studies and contributed samples to the GWAS and/or follow-up genotyping. All authors contributed to the writing of the manuscript.

COMPETING INTERESTS

The authors declare no competing financial interests

4.0), but not indolent lymphomas⁴. Among candidate gene studies investigating susceptibility to DLBCL, only one locus, the *LTA252G/TNF-308A* haplotype on chromosome 6p21, reached genome-wide significance ($P=2.9\times 10^{-8}$)⁵. In small GWAS of all NHL subtypes combined, no conclusive loci for NHL or DLBCL were identified in individuals of European background⁶⁻⁹, whereas a recent study conducted in East Asia identified a locus at 3q27¹⁰.

To discover new DLBCL susceptibility loci, in stage 1, we genotyped 2,878 DLBCL cases and 2,854 controls of European ancestry from 22 studies using the Illumina OmniExpress Beadchip (**Online Methods**; Supplementary Table 1; Supplementary Figure 1). A total of 5,346 (93.3%) samples and 611,844 SNPs successfully passed rigorous quality control criteria (**Online Methods**; Supplementary Table 2). To augment the number of controls, genotype data from 3,536 cancer-free controls previously analyzed with the Omni2.5 SNP microarray were folded into the analytical build¹¹, resulting in a total of 2,661 cases and 6,221 controls for the stage 1 GWAS analysis (Supplementary Table 2).

In stage 1, with adjustment for gender, age and four eigenvectors (**Online Methods**), we observed an enrichment of SNPs with smaller P -values compared to the null distribution in the Q-Q plot with a lambda of 1.016 (Supplementary Figure 2). Two SNPs exceeded the threshold for genome-wide significance ($P<5\times 10^{-8}$) whereas 20 SNPs showed highly suggestive associations ($P<5\times 10^{-7}$) (Supplementary Figure 3). All but one SNP mapped to the HLA region of chromosome 6 (29.5Mb to 33.2Mb on Human Genome version 19 coordinates).

In stage 2, we included data from two unpublished and previously genotyped GWAS (GELA/EPIC and Mayo) plus one published GWAS (UCSF⁷), totaling 1,196 DLBCL cases and 1,445 controls (**Online Methods**; Supplementary Tables 1, 3). Because different genotyping platforms were used, we imputed common SNPs for each study based on the 1000 Genomes Project release version 3¹² and IMPUTE2¹³ (Supplementary Table 4). In meta-analysis of all genotyped and high-quality imputed SNPs from stages 1 and 2 ($N=8,363,971$), we identified 19 SNPs at genome-wide significance ($P<5\times 10^{-8}$) (Supplementary Table 5) and 134 SNPs at a suggestive level of significance ($P<5\times 10^{-7}$) (Supplementary Table 6); 123 of the 153 total SNPs mapped to the HLA region on chromosome 6. Based on these results, we selected and successfully designed TaqMan primers for eight promising SNPs ($P<5\times 10^{-6}$) outside the HLA region and one SNP from the HLA region for stage 3 *de novo* genotyping in an additional 1,359 DLBCL cases and 4,557 controls (**Online Methods**; Supplementary Tables 1, 3).

In a meta-analysis of all three stages (Supplementary Table 7), we identified four non-HLA SNPs in three novel loci at 6p25.3 (rs116446171, $P=2.33\times 10^{-21}$) near *EXOC2*, 8q24.21 (rs13255292, $P=9.98\times 10^{-13}$; rs4733601, $P=3.63\times 10^{-11}$) near *PVT1* and *MYC*, and 2p23.3 (rs79480871, $P=4.23\times 10^{-8}$) near *NCOA1* (Table 1; Figures 1a-c). The two 8q24.21 SNPs displayed minimal linkage disequilibrium (LD, $r^2=0.03$ in 1000 Genomes CEU population). Furthermore, in conditional analysis, both rs13255292 (conditional OR=1.22, $P=1.39\times 10^{-12}$) and rs4733601 (conditional OR=1.18, $P=2.84\times 10^{-10}$) remained genome-wide significant; together these data support the presence of two independent SNPs associated

with DLBCL at 8q24.21. We also observed two suggestive SNPs ($P < 5 \times 10^{-7}$) (Supplementary Table 8), one at 5q31.3 (rs79464052, $P = 5.57 \times 10^{-8}$) in *ARAP3* (Supplementary Figure 4), and one at 3q13.33 (rs2681416), although the latter SNP did not replicate in stage 2 or 3.

Within the HLA region, rs2523607 ($P = 3.35 \times 10^{-9}$) was carried forward for replication in stage 3. This SNP, localized at 6p21 in *HLA-B*, reached a combined $P = 2.40 \times 10^{-10}$ in a meta-analysis of all three stages (Table 1; Figure 1d). To further evaluate the association of HLA variants with DLBCL risk, we imputed classical HLA alleles at six loci (*HLA-A*, *B*, *C*, *DRB1*, *DQA1*, and *DQB1*) in the four GWAS datasets from stages 1–2 and conducted a meta-analysis (**Online Methods**). The imputation accuracy of HLA types was high (>95.2%) when compared to HLA sequencing (four-digit resolution) previously performed on a subset of the NCI samples¹⁴ scanned as part of this study in stage 1 (**Online Methods**). Of all SNPs and classical HLA alleles tested across the MHC, only the SNP rs2523607 (OR=1.34, $P = 3.3 \times 10^{-9}$ in stages 1 and 2) and the classical allele *HLA-B*08:01* (OR=1.30, $P = 3.16 \times 10^{-8}$ in stages 1 and 2) reached genome-wide significance (Supplementary Table 9). These markers were in very high LD ($r^2 = 0.91$), and after adjusting for the effect of *HLA-B*08:01*, the association of rs2523607 was greatly weakened ($P = 5.5 \times 10^{-3}$).

To gain additional insight into potential biological mechanisms, expression quantitative trait loci (eQTL) analyses were performed in two datasets consisting of lymphoblastoid cell lines (**Online Methods**). In one of the datasets, significant associations were observed for rs116446171 with *HIST1H3F* and rs2523607 with *HCG27* (Supplementary Table 10), while in the other dataset significant associations (FDR < 0.05) were observed for rs2523607 (using rs3130923 as a proxy, $r^2 = 0.94$) with *LY6G6E*, *FLOT1*, and *RNF5* (Supplementary Table 11); no associations were observed for the other DLBCL-associated loci.

To explore plausible mechanisms for the non-coding variants identified in our GWAS, the sentinel SNPs and those in high linkage disequilibrium ($r^2 \geq 0.8$) in Europeans in the 1000 Genomes Project were analyzed using HaploReg v2¹⁵ (**Online Methods**; Supplementary Table 12). In addition, B-cell specific chromatin dynamics were assessed in a lymphoblastoid cell line (GM12878) using ChroMoS¹⁶, which utilizes the pre-computed chromatin state data for 9 cell lines (including GM12878)¹⁷. Of the 173 SNPs queried, 61 had information for GM12878 (Supplementary Figure 5), and 3 SNPs were identified as active or weak promoters only in GM12878, while 22 SNPs were identified as strong or weak enhancers in GM12878. In the other 8 cell lines, these regions were mostly defined as neutral, weakly transcribed or polycomb repressed. These results suggest that some of our SNPs are within regions of active chromatin state predominantly within B cells and have a role in the B-cell cis-regulatory network. These results are consistent with growing evidence that disease variants from GWAS are more likely to map to active chromatin sites than neutral sites, as was shown recently for systemic lupus erythematosus¹⁷. HaploReg showed that the majority of DLBCL-related SNPs were observed in regions of DNase hypersensitivity common across multiple cell lines (e.g., rs116446171, rs2523607, rs13255292, rs4733601 near *EXOC2*, *HLA-B*, *PVT1* or *7SK*) whereas rs147193201 was specific to B-cells. The preponderance of DNase hypersensitivity points to the existence of motifs, such as enhancers, silencers, promoters, insulators and other control elements of

gene regulation. The proteins bound at these sites are known transcription factors such as NF- κ B, c-MYC, GATA2 or genes that regulate transcription such as *POL24H8*, *USF1* or *POL2*. These suggested mechanisms of action will require laboratory follow-up.

The susceptibility locus at 6p25.3 (rs116446171) maps near a plausible DLBCL candidate gene, *EXOC2* (exocyst complex component 2), which is part of a large multiprotein complex responsible for vesicle trafficking and maintenance and intercellular transfer of viral proteins and virions¹⁸. *EXOC2* functions at the interface between host defense and cell death regulation¹⁹. *EXOC2* interacts with Ral proteins, and the Ral-exocyst regulatory node has a crucial role in the maintenance of epithelial cell polarity, cell motility and cytokinesis^{20,21}, and in proliferation and metastasis^{20,22}. It is notable that *IRF4* is centromeric to *EXOC2* and genetic variation in this region has been linked with chronic lymphocytic leukemia (CLL) risk^{23,24}, and nominally to DLBCL risk²⁵. However, rs116446171 was not in LD with the *IRF4* CLL GWAS SNP rs872071²³.

Two 8q24.21 variants (Figure 1b), rs13255292 and rs4736601 positioned at chr8:129.07Mb and chr8:129.26Mb, respectively, are approximately 1Mb telomeric to the 8q24 region linked with multiple cancers²⁶, including CLL²⁷. Both variants are in close proximity to *PVT1*, which is a non-coding RNA implicated in the MYC activation. Notably, a variant at 8q24.21 (rs2019960) has been linked to HL²⁸, but the pair-wise r^2 values of this SNP with both of our SNPs were low ($r^2 < 0.02$). The close proximity of *PVT1* and the *MYC* oncogene, which is known to be deregulated in Burkitt lymphoma^{29,30} and some DLBCLs^{31,32}, suggests that germline variation in this region could also contribute to DLBCL risk.

The susceptibility locus at 2p23.3 (rs79480871) maps near *NCOA1*, nuclear receptor coactivator 1 and *ITSN2*, intersectin 2. The former gene acts as a transcriptional coactivator for steroid and nuclear hormone receptors and is a member of the p160/steroid receptor coactivator (SRC) family³³, while the latter gene encodes a protein that is a member of a family of proteins involved in clathrin-mediated endocytosis³⁴ and may also augment the induction of T-cell receptor endocytosis³⁵. However, our bioinformatics analysis did not identify a clear link to genes in this region, supporting the need to refine this signal in future work.

Through imputation with SNP2HLA,³⁶ our strongest associations in the HLA region were with the *HLA-B* SNP rs2523607 and *HLA-B*08:01*, which are in very high LD, and based on our available sample size we cannot definitively rule out an orthogonal effect of rs2523607 in favor of *HLA-B*08:01*. *HLA-B* encodes the HLA class I heavy chain paralogue, which heterodimerizes with a light chain (β_2 microglobulin) to play a central role in presenting intracellularly processed self or foreign antigens to CD8⁺ cytotoxic T lymphocytes. Class I molecules have been linked to a variety of immune-mediated diseases and cancers including HL, follicular lymphoma, DLBCL^{7,14,37,38}, and more recently marginal zone lymphoma (Vijai, submitted). Our results strongly suggest *HLA-B*08:01* as the primary MHC association with DLBCL risk. This classical allele is carried by the so-called ancestral 8.1 haplotype associated with other complex diseases (e.g., type I diabetes).³⁹ Classical alleles of other HLA loci may also be involved (including those on the 8.1 haplotype), but larger sample sizes will be required to evaluate this question.

Our study represents the largest DLBCL GWAS in individuals of European descent. We did not observe a notable signal for a locus previously reported for DLBCL on 3q27 in East Asia¹⁰, rs6773854 (reported as OR=1.47, $P=1.14\times 10^{-11}$), which was based on a discovery set of 253 B-cell NHL cases (148 DLBCLs). Although our current study had a similar MAF of 0.22 among controls, we observed an OR=1.06 and a P -value of 0.81 for this SNP (Supplementary Table 13), suggesting that the reported marker may not be correlated with the functional susceptibility allele in Europeans. Of the two suggestive loci ($P<5\times 10^{-7}$) reported in the literature^{8,40}, we did not observe an association for rs751837 with DLBCL (OR=0.97, $P=0.46$), identified in a small Japanese GWAS (OR=3.51, $P=3.3\times 10^{-7}$)⁴⁰, but we did observe a consistent albeit attenuated association for rs10484561 (OR=1.18, $P=1.5\times 10^{-4}$) which was initially reported on a subset of the studies in stage 1 (OR=1.36, $P=1.46\times 10^{-7}$)⁸. Previously, an InterLymph study of ~1,800 DLBCLs and ~6,500 controls reported a strong signal for a dinucleotide haplotype in the *LTA/TNF* locus (*LTA* 252A>G/*TNF*-308G>A) at 6p21.3 (OR=1.31, $P=2.9\times 10^{-8}$)⁵. Although nearly all of the cases from the previous publication were included in our current GWAS, the signal we observed overall was weaker (OR=1.15, $P=8.5\times 10^{-4}$). The attenuation was not explained by study design (case-control, cohort) or adjustment for population substructure (data not shown), but could be due to population sampling differences, heterogeneity, or chance.

To explore the heritability of DLBCL, we estimated the contribution of all common SNPs to the variance explained by fitting all genotyped autosomal SNPs simultaneously using the method proposed by Yang et al⁴¹ in the Stage 1 dataset. We estimated that common SNPs, including but not limited to the loci discovered in this study, explain approximately 16% of the variance for DLBCL overall.

In summary, our findings represent an important step in defining the contribution of common genetic variants to risk for DLBCL. Our findings are notable because we have newly defined associations of several regions with susceptibility to DLBCL, and these regions harbor plausible candidate genes for further investigation. Further studies are required to discover additional common susceptibility loci as well as functional analyses that can explain the biological underpinnings of these new susceptibility loci.

ONLINE METHODS

Stage 1: DLBCL-GWAS

As part of a larger initiative, we conducted a genome-wide association study (GWAS) of diffuse large B-cell lymphoma (DLBCL) using cases and controls of European descent from 22 studies of non-Hodgkin lymphoma (NHL) (Supplementary Table 1), including nine prospective cohort studies, eight population-based case-control studies, and five clinic or hospital-based case-control studies. All studies were approved by their respective Institutional Review Boards, and informed consent was obtained for all participants. Cases were ascertained from cancer registries, clinics or hospitals, or through self-report verified by medical and pathology reports. To determine NHL subtype, phenotype data for all NHL cases were harmonized to the hierarchical classification proposed by the InterLymph Pathology Working Group^{42,43} based on the World Health Organization (WHO) classification⁴⁴.

All DLBCL cases with sufficient DNA (n=2,878) and a subset of controls (n=2,854) frequency matched by age, sex, and study to the entire group of NHL cases, along with 4% quality control duplicates, were genotyped on the Illumina OmniExpress at the NCI Cancer Genomic Research Laboratory (CGR). Genotypes were called using Illumina GenomeStudio software, and quality control duplicates showed >99% concordance. Monomorphic SNPs and SNPs with a call rate of <95% were excluded. Samples with a call rate of <93%, mean heterozygosity <0.25 or >0.33 based on the autosomal SNPs, or gender discordance (>5% heterozygosity on X chromosome for males and <20% heterozygosity on the X chromosome for females) were excluded. Furthermore, unexpected duplicates (>99.9% concordance) and first-degree relatives based on identity by descent (IBD) sharing with $\hat{\pi} > 0.40$ were excluded. Ancestry was assessed using the GLU *struct.admix* module based on the method by Pritchard et al.⁴⁵ and participants with <80% European ancestry were excluded (Supplementary Figure 6). After exclusions, 2,661 (92.5%) cases and 2,685 (94.1%) controls remained (Supplementary Table 2). Genotype data previously generated on the Illumina Omni2.5 from an additional 3,536 controls from three of the studies (ATBC, CPSII, and PLCO) were also included¹¹, resulting in a total of 2,661 cases and 6,221 controls for the stage 1 analysis. Of these additional 3,536 controls, 703 (~235 from each study) were selected to be representative of their cohort and cancer-free¹¹, while the remainder were cancer-free controls from an unpublished study of prostate cancer in the PLCO. SNPs with call rate <95%, with Hardy-Weinberg equilibrium *P*-value < 1×10^{-6} , or with a minor allele frequency <1% were excluded from analysis, leaving 611,844 SNPs for analysis (Supplementary Table 4). To evaluate population substructure, a principal components analysis (PCA) was performed using the Genotyping Library and Utilities (GLU), version 1.0, *struct.pca* module, which is similar to EIGENSTRAT⁴⁶. Plots of the first five principal components are shown in Supplementary Figure 7. Association testing was conducted assuming a log-additive genetic model, adjusting for age, sex, and four significant principal components. All data analysis and management was conducted using GLU.

Stage 2: In Silico Analysis of Three Independent DLBCL GWAS

Three independent DLBCL GWAS provided genotyping data for a meta-analysis, (Supplementary Table 1), which included data generated with the following commercial, SNP microarrays: Illumina HumanHap 660W for Mayo (393 DLBCL and 172 controls), HumanCNV370-Duo for UCSF⁷ (254 DLBCLs and 748 controls), and HumanHap 610K for GELA (549 cases). In all studies, subjects with a genotyping call rate <95%, duplicates, related individuals, and SNPs with a call rate <95% were removed prior to imputation (Supplementary Table 4). The GELA study was conducted on cases only; controls were drawn from a pool of 928 individuals from the French component of the EPIC cohort, who were previously scanned on Illumina HumanHap 660W or 610K^{47,48}. We subsequently chose a subset of 525 individuals with matched ancestry as determined from the principal components analysis. In total, there were 1,196 cases and 1,445 controls in stage 2.

Imputation was conducted separately for each study in stages 1 and 2 using IMPUTE2¹³ and the 1000 Genomes Project version 3¹². The imputation analysis was restricted to common SNPs (cut-off MAF > 0.01 with imputation accuracy INFO score > 0.3).

Association testing was conducted for each study using SNPTTEST version 2, adjusting for age, sex, and any significant principal components. We evaluated the top 10 eigenvectors for the GELA, Mayo and UCSF studies, respectively, in each baseline risk model adjusting for both age and gender. Based on the significance level ($P < 0.05$) of the regression coefficient for eigenvectors, we chose to adjust for three eigenvectors (EV1, EV7 and EV8) for GELA in the final association model, while no eigenvectors met criteria for adjustment of either the Mayo or UCSF studies.

All meta-analyses were performed using the fixed effects inverse variance method based on the beta estimates and standard errors from each study.

Stage 3: Replication studies and technical validation

In stage 3, eight SNPs in the most promising loci outside of the HLA region and one SNP from the HLA region (Supplementary Table 7) were taken forward for *de novo* replication in an additional 1359 cases and 4557 controls from four studies (Supplementary Table 1), except for rs2523607, which was not genotyped in one of the studies (NCI replication). Genotyping was conducted using custom TaqMan genotyping assays (Applied Biosystems) at the NCI Cancer Genomics Research Laboratory. Each assay was optimized and validated with 270 HapMap samples and additional CEPH samples (SNP500Cancer), and these samples were used as genotyping controls for clustering and reproducibility. All validated assays had 99% or higher concordance with HapMap and completion with control DNA was >97%. Blind duplicates from stage 3 samples (64 pairs; ~3%) yielded 100% concordance.

In technical validation, we observed a high correlation of genotyping calls from the OmniExpress microarray with confirmatory TaqMan assays in 455 stage 1 duplicate samples for two genotyped (rs13255292, $r^2=1.00$; rs4733601, $r^2=1.00$) and four imputed (rs116446171, $r^2=0.92$; rs2523607, $r^2=0.99$; rs2681416, $r^2=1.00$; rs79480871, $r^2=0.94$) SNPs. We also observed a high correlation of genotyping calls from the Illumina HumanHap 660W microarray with confirmatory TaqMan assays in stage 2 duplicate samples from the Mayo study (N=165) for two genotyped (rs13255292, $r^2=1.00$; rs4733601, $r^2=1.00$) and four imputed (rs116446171, $r^2=1.00$; rs2523607, $r^2=1.00$; rs79480871, $r^2=0.85$; rs79464052, $r^2=0.95$) SNPs.

HLA imputations and analysis

We imputed dense SNPs as well as classical HLA alleles (*A*, *B*, *C*, *DRB1*, *DQA1*, *DQB1*) and coding variants across the HLA region (chr6:29.5–33.2Mb, hg19) in the stage 1 (NCI) and stage 2 (MAYO, USCF2 and GELA/EPIC) studies using SNP2HLA³⁶. The imputation was based on a reference panel from the Type 1 Diabetes Genetics Consortium (T1DGC), and consisted of genotypes from 5,225 individuals of European descent who were typed for *HLA-A*, *B*, *C*, *DQA1*, *DQB1*, *DRB1*, *DPA1*, *DPB1* 4 digit alleles. To assess imputation accuracy, we compared the imputed HLA alleles to HLA sequencing data (to 4 digits) available on a subset of samples from the NCI GWAS¹⁴, and found high concordance rates for *HLA-A* (97.3%), *B* (98.5%), *C* (98.1%) and *DRB1* (97.5%). Due to the limited number of SNPs (N=7,253) in the T1DGC reference set, imputation of HLA SNPs was conducted with IMPUTE2 and the 1000 Genomes reference set as described above. A total of 68,488 SNPs,

201 classical HLA alleles (two- and four-digit resolution) and 1,038 AA markers including 103 AA positions that were ‘multi-allelic’ with three to six different residues present at each position, were successfully imputed (info score >0.3 for SNPs or $r^2>0.3$ for alleles and AAs) and available for analysis. Multi-allelic markers were analyzed as binary markers (e.g., allele present or absent) and using a global test, and a meta-analysis was conducted where we tested SNPs, HLA alleles and AAs across the HLA region for association with DLBCL using PLINK⁴⁹ or SNPTEST as described above.

Expression quantitative trait loci (eQTL) analysis

To evaluate the effect of our top loci (and SNPs in LD based on $r^2>0.8$ in HapMap-CEU release 28) on gene expression, we conducted an eQTL analysis on lymphoblastoid cell lines using two independent datasets: Childhood asthma⁵⁰ and HapMap⁵¹. For the childhood asthma dataset⁵⁰, peripheral blood lymphocytes were transformed into lymphoblastoid cell lines for 830 parents and offspring from 206 families of European ancestry. Using extracted RNA, gene expression was assessed with the Affymetrix HG-U133 Plus 2.0 chip. Genotyping was conducted using the Illumina Human1M Beadchip and Illumina HumanHap300K Beadchip, and imputation was performed using data from the 1kGP. All SNPs selected for replication were tested for *cis* associations (defined as gene transcripts within 1 Mb), assuming an additive genetic model, adjusting for non-genetic effects in the gene expression value. To gain insight into the relative importance of associations with our SNPs compared to other SNPs in the region, we also conducted conditional analyses, in which both the DLBCL SNP and the most significant SNP for the particular gene transcript (i.e., peak SNP) were included in the same model. Only *cis* associations that reached $P<6.8\times 10^{-5}$, which corresponds to a false-discovery rate (FDR) of 1%, are reported (Supplementary Table 10).

The HapMap dataset consisted of a publicly available RNAseq dataset⁵¹ from transformed lymphoblastoid cell lines from 41 CEPH Utah residents with ancestry from northern and western Europe (HapMap-CEU), samples available from the Gene Expression Omnibus (GEO) repository (<http://www.ncbi.nlm.nih.gov/geo>) under accession number GSE16921. Genotyping data for the same HapMap-CEU individuals were directly downloaded from HapMap (www.hapmap.org). Since rs2523607, rs79480871 and rs116446171 were not genotyped in HapMap, we selected rs3130923, rs6746301 and rs7762424 as respective proxies, as they were the strongest linked SNPs available in HapMap ($r^2=0.94, 0.69$ and 0.54 in 1kGP-CEU, respectively). Correlation between expression and genotype for each SNP-probe pair was tested using the Spearman’s rank correlation test with t-distribution approximation and were estimated with respect to the minor allele in HapMap-CEU. *P*-values were adjusted using the Benjamini-Hochberg false-discovery rate (FDR) correction and eQTLs were considered significant at an FDR 0.05 (Supplementary Table 11).

Bioinformatics: ENCODE and Chromatin State Dynamics

Using 1000 Genomes data, we identified SNPs with $r^2 \geq 0.8$ with our sentinel SNP that were reported to be non-synonymous or nonsense variants. We utilized HaploReg v2¹⁵, which is a tool for exploring non-coding functional annotation using ENCODE data, to evaluate the genome surrounding our SNPs (Supplementary Table 12). To assess chromatin state

dynamics, we used Chromos¹⁶, which has pre-computed data from ENCODE on 9 cell types based on Chip-Seq analyses¹⁷. These pre-computed data have genome-segmentation performed using multivariate hidden Markov-model to reduce the combinatorial space to a set of interpretable chromatin states. The output from Chromos separates data into 15 chromatin states corresponding to repressed, poised and active promoters, strong and weak enhancers, putative insulators, transcribed regions, and large-scale repressed and inactive domains (Supplementary Figure 5).

Heritability analyses

To estimate the contribution of all common SNPs to the variance explained, we used the method proposed by Yang et al⁴¹, which was extended to dichotomous traits⁵² and implemented in the Genome-wide Complex Trait Analysis (GCTA) software⁵³. The genetic similarity matrix was estimated from our stage 1 data using all genotyped autosomal SNPs with a minor allele frequency >0.01. We used restricted maximum likelihood (REML), the default option for GCTA, to fit the appropriate variance components model that included the top 10 eigenvectors as covariates. The final estimate of heritability on the underlying liability scale assumed that the lifetime risk of DLBCL was 0.0074⁵⁴.

Estimate of recombination hotspots

To identify recombination hotspots in the region we used SequenceLDhot⁵⁵, a program that uses the approximate marginal likelihood method⁵⁶ and calculates likelihood ratio statistics at a set of possible hotspots. We tested five unique sets of 100 control samples. PHASE v2.1 program was used to calculate background recombination rates^{57,58} and LD heatmap was visualized in r2 using snp.plotter program⁵⁹.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

James R Cerhan^{1,94}, Sonja I Berndt^{2,94}, Joseph Vijai^{3,94}, Hervé Ghesquière^{4,5,94}, James McKay^{6,94}, Sophia S Wang^{7,94}, Zhaoming Wang^{8,94}, Meredith Yeager⁸, Lucia Conde^{9,10}, Paul I W de Bakker^{11,12}, Alexandra Nieters¹³, David Cox¹⁴, Laurie Burdett⁸, Alain Monnereau^{15,16,17}, Christopher R Flowers¹⁸, Anneclaire J De Roos^{19,20}, Angela R Brooks-Wilson^{21,22}, Qing Lan², Gianluca Severi^{23,24,25}, Mads Melbye^{26,27}, Jian Gu²⁸, Rebecca D Jackson²⁹, Eleanor Kane³⁰, Lauren R Teras³¹, Mark P Purdue², Claire M Vajdic³², John J Spinelli^{33,34}, Graham G Giles^{24,25}, Demetrius Albanes², Rachel S Kelly^{35,36}, Mariagrazia Zucca³⁷, Kimberly A Bertrand^{35,38}, Anne Zeleniuch-Jacquotte^{39,40}, Charles Lawrence⁴¹, Amy Hutchinson⁸, Degui Zhi⁴², Thomas M Habermann⁴³, Brian K Link⁴⁴, Anne J Novak⁴³, Ahmet Dogan⁴⁵, Yan W Asmann⁴⁶, Mark Liebow⁴³, Carrie A Thompson⁴³, Stephen M Ansell⁴³, Thomas E Witzig⁴³, George J Weiner⁴⁴, Amelie S Veron¹⁴, Diana Zelenika⁴⁷, Hervé Tilly⁴⁸, Corinne Haioun⁴⁹, Thierry Jo Molina⁵⁰, Henrik Hjalgrim²⁶, Bengt Glimelius^{51,52}, Hans-Olov Adami^{35,53}, Paige M Bracci⁵⁴, Jacques

Riby^{9,10}, Martyn T Smith¹⁰, Elizabeth A Holly⁵⁴, Wendy Cozen^{55,56}, Patricia Hartge², Lindsay M Morton², Richard K Severson⁵⁷, Lesley F Tinker²⁰, Kari E North^{58,59}, Nikolaus Becker⁶⁰, Yolanda Benavente^{61,62}, Paolo Boffetta⁶³, Paul Brennan⁶⁴, Lenka Foretova⁶⁵, Marc Maynadie⁶⁶, Anthony Staines⁶⁷, Tracy Lightfoot³⁰, Simon Crouch³⁰, Alex Smith³⁰, Eve Roman³⁰, W Ryan Diver³¹, Kenneth Offit³, Andrew Zelenetz³, Robert J Klein³, Danylo J Villano³, Tongzhang Zheng⁶⁸, Yawei Zhang⁶⁸, Theodore R Holford⁶⁹, Anne Krickler⁷⁰, Jenny Turner^{71,72}, Melissa C Southey⁷³, Jacqueline Clavel^{15,16}, Jarmo Virtamo⁷⁴, Stephanie Weinstein², Elio Riboli⁷⁵, Paolo Vineis^{23,36}, Rudolph Kaaks⁶⁰, Dimitrios Trichopoulos^{35,76,77}, Roel C H Vermeulen^{12,78}, Heiner Boeing⁷⁹, Anne Tjonneland⁸⁰, Emanuele Angelucci⁸¹, Simonetta Di Lollo⁸², Marco Rais⁸³, Brenda M Birmann³⁸, Francine Laden^{35,38,84}, Edward Giovannucci^{35,38,85}, Peter Kraft^{35,86}, Jinyan Huang³⁵, Baoshan Ma^{35,87}, Yuanqing Ye²⁸, Brian C H Chiu⁸⁸, Joshua Sampson², Liming Liang^{35,86}, Ju-Hyun Park⁸⁹, Charles C Chung², Dennis D Weisenburger⁹⁰, Nilanjan Chatterjee², Joseph F Fraumeni Jr², Susan L Slager¹, Xifeng Wu^{28,95}, Silvia de Sanjose^{61,62,95}, Karin E Smedby^{91,95}, Gilles Salles^{5,92,93,95}, Christine F Skibola^{9,10,95}, Nathaniel Rothman^{2,95}, and Stephen J Chanock^{2,95}

Affiliations

¹Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA ²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA ³Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA ⁴Department of Hematology, Centre Léon Bérard, Lyon, France ⁵Laboratoire de Biologie Moléculaire de la Cellule UMR 5239, Centre National de la Recherche Scientifique, Pierre benite Cedex, France ⁶Genetic Cancer Susceptibility Group, Section of Genetics, International Agency for Research on Cancer, Lyon, France ⁷Department of Cancer Etiology, City of Hope Beckman Research Institute, Duarte, California, USA ⁸Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Gaithersburg, Maryland, USA ⁹Department of Epidemiology, School of Public Health and Comprehensive Cancer Center, Birmingham, Alabama, USA ¹⁰Division of Environmental Health Sciences, University of California Berkeley School of Public Health, Berkeley, California, USA ¹¹Department of Medical Genetics and of Epidemiology, University Medical Center Utrecht, Utrecht, The Netherlands ¹²Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands ¹³Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Baden-Württemberg, Germany ¹⁴Léon-Bérard Cancer Center, Cancer Research Center of Lyon, Lyon, France ¹⁵Environmental Epidemiology of Cancer Group, Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Villejuif, France ¹⁶UMRS 1018, Univ Paris Sud, Villejuif, France ¹⁷Registre des hémopathies malignes de la Gironde, Institut Bergonié, Bordeaux Cedex, France ¹⁸Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA ¹⁹Department of Environmental and Occupational Health, Drexel University School

of Public Health, Philadelphia, Pennsylvania, USA ²⁰Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ²¹Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada ²²Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada ²³Human Genetics Foundation, Turin, Italy ²⁴Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia ²⁵Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia ²⁶Department of Epidemiology Research, Division of Health Surveillance and Research, Statens Serum Institut, Copenhagen, Denmark ²⁷Department of Medicine, Stanford University School of Medicine, Stanford, California, USA ²⁸Department of Epidemiology, M.D. Anderson Cancer Center, Houston, Texas, USA ²⁹Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, Ohio, USA ³⁰Department of Health Sciences, University of York, York, United Kingdom ³¹Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, USA ³²Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia ³³Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada ³⁴School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada ³⁵Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA ³⁶MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom ³⁷Department of Biomedical Science, University of Cagliari, Monserrato, Cagliari, Italy ³⁸Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA ³⁹Department of Population Health, New York University School of Medicine, New York, New York, USA ⁴⁰Cancer Institute, New York University School of Medicine, New York, New York, USA ⁴¹Health Studies Sector, Westat, Rockville, Maryland, USA ⁴²Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA ⁴³Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA ⁴⁴Department of Internal Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA ⁴⁵Departments of Laboratory Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA ⁴⁶Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Minnesota, USA ⁴⁷Centre National de Génotypage, Evry, France ⁴⁸Centre Henri Becquerel, Rouen, France ⁴⁹Department of Hematology, CHU Henri Mondor, Creteil, France ⁵⁰Department of Pathology, AP-HP, Necker Enfants Malades, Université Paris Descartes, Sorbonne Paris Cité, France ⁵¹Department of Oncology and Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden ⁵²Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden ⁵³Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ⁵⁴Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA ⁵⁵Department of Preventive Medicine, USC Keck School of Medicine, University of

Southern California, Los Angeles, California, USA ⁵⁶Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California, USA ⁵⁷Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, Michigan, USA ⁵⁸Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ⁵⁹Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ⁶⁰Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany ⁶¹Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d'Oncologia, IDIBELL, Barcelona, Spain ⁶²Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain ⁶³The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA ⁶⁴Group of Genetic Epidemiology, Section of Genetics, International Agency for Research on Cancer, Lyon, France ⁶⁵Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and MF MU, Brno, Czech Republic ⁶⁶EA 4184, Registre des Hémopathies Malignes de Côte d'Or, University of Burgundy and Dijon University Hospital, Dijon, France ⁶⁷School of Nursing and Human Sciences, Dublin City University, Dublin, Ireland ⁶⁸Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut, USA ⁶⁹Department of Biostatistics, Yale School of Public Health, New Haven, Connecticut, USA ⁷⁰Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia ⁷¹Pathology, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales, Australia ⁷²Department of Histopathology, Douglass Hanly Moir Pathology, Macquarie Park, New South Wales, Australia ⁷³Department of Pathology, University of Melbourne, Parkville, Victoria, Australia ⁷⁴Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland ⁷⁵School of Public Health, Imperial College London, London, United Kingdom ⁷⁶Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece ⁷⁷Hellenic Health Foundation, Athens, Greece ⁷⁸Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands ⁷⁹Department of Epidemiology, German Institute for Human Nutrition, Potsdam, Germany ⁸⁰Danish Cancer Society Research Center, Copenhagen, Denmark ⁸¹Hematology Unit, Ospedale Oncologico di Riferimento Regionale A. Businco, Cagliari, Italy ⁸²Department of Surgery and Translational Medicine, Section of Anatomic-Pathology, University of Florence, Florence, Italy ⁸³Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, Monserrato, Cagliari, Italy ⁸⁴Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA ⁸⁵Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA ⁸⁶Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA ⁸⁷College of Information Science and Technology, Dalian Maritime University, Dalian, Liaoning Province, China ⁸⁸Department of Health Studies, University of Chicago, Chicago, Illinois, USA ⁸⁹Dongguk University-Seoul, Seoul, South Korea ⁹⁰Department of Pathology, City of Hope National Medical

Center, Duarte, California, USA ⁹¹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden ⁹²Department of Hematology, Hospices Civils de Lyon, Pierre benite Cedex, France ⁹³Department of Hematology, Université Lyon-1, Pierre benite Cedex, France

Acknowledgments

We thank C. Allmer, E. Angelucci, A. Bigelow, S. Buehler, K. Butterbach, A. Chabrier, J.M. Connors, M. Corines, M. Cornelis, K. Corsano, H. Dykes, L. Ershler, A. Gabbas, R.P. Gallagher, R.D. Gascoyne, P. Hui, L. Irish, L. Jacobus, L. Klareskog, A.S. Lai, J. Lunde, M. McAdams, R. Montalvan, L. Padyukov, M. Rais, T. Rattle, L. Rigacci, K. Snyder, G. Specchia, M. Stagner, G. Thomas, C. Tornow, G. Wood, and M. Yang.



The overall GWAS project was supported by the intramural program of the US National Institutes of Health/ National Cancer Institute. A list of support provided to individual studies is provided in the Supplementary Note.


References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin.* 2013; 63:11–30. [PubMed: 23335087]
2. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. *CA Cancer J Clin.* 2010; 60:393–408. [PubMed: 21030533]
3. Wang SS, et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). *Blood.* 2007; 109:3479–88. [PubMed: 17185468]
4. Goldin LR, Bjorkholm M, Kristinsson SY, Turesson I, Landgren O. Highly increased familial risks for specific lymphoma subtypes. *Br J Haematol.* 2009; 146:91–4. [PubMed: 19438470]
5. Skibola CF, et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. *Am J Epidemiol.* 2010; 171:267–76. [PubMed: 20047977]
6. Skibola CF, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. *Nat Genet.* 2009; 41:873–5. [PubMed: 19620980]
7. Conde L, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. *Nat Genet.* 2010; 42:661–4. [PubMed: 20639881]
8. Smedby KE, et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. *PLoS Genet.* 2011; 7:e1001378. [PubMed: 21533074]
9. Vijai J, et al. Susceptibility Loci associated with specific and shared subtypes of lymphoid malignancies. *PLoS genetics.* 2013; 9:e1003220. [PubMed: 23349640]
10. Tan DE, et al. Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. *Nat Genet.* 2013; 45:804–7. [PubMed: 23749188]
11. Wang Z, et al. Improved imputation of common and uncommon SNPs with a new reference set. *Nat Genet.* 2012; 44:6–7. [PubMed: 22200770]
12. Abecasis GR, et al. A map of human genome variation from population-scale sequencing. *Nature.* 2010; 467:1061–73. [PubMed: 20981092]
13. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet.* 2009; 5:e1000529. [PubMed: 19543373]
14. Wang SS, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. *Blood.* 2010; 115:4820–3. [PubMed: 20385791]
15. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* 2012; 40:D930–4. [PubMed: 22064851]

16. Barenboim M, Manke T. ChroMoS: an integrated web tool for SNP classification, prioritization and functional interpretation. *Bioinformatics*. 2013; 29:2197–8. [PubMed: 23782616]
17. Ernst J, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. *Nature*. 2011; 473:43–9. [PubMed: 21441907]
18. Mukerji J, Olivieri KC, Misra V, Agopian KA, Gabuzda D. Proteomic analysis of HIV-1 Nef cellular binding partners reveals a role for exocyst complex proteins in mediating enhancement of intercellular nanotube formation. *Retrovirology*. 2012; 9:33. [PubMed: 22534017]
19. Mantovani A, Balkwill F. RalB signaling: a bridge between inflammation and cancer. *Cell*. 2006; 127:42–4. [PubMed: 17018274]
20. Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. *Nat Rev Cancer*. 2008; 8:133–40. [PubMed: 18219307]
21. Issaq SH, Lim KH, Counter CM. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis. *Mol Cancer Res*. 2010; 8:223–31. [PubMed: 20145037]
22. Kashatus DF. Ral GTPases in tumorigenesis: emerging from the shadows. *Exp Cell Res*. 2013; 319:2337–42. [PubMed: 23830877]
23. Di Bernardo MC, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. *Nat Genet*. 2008; 40:1204–10. [PubMed: 18758461]
24. Berndt SI, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nat Genet*. 2013; 45:868–76. [PubMed: 23770605]
25. Wang SS, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF- κ B transcription factors and non-Hodgkin lymphoma risk. *PLoS One*. 2009; 4:e5360. [PubMed: 19390683]
26. Wacholder S, Yeager M, Liao LM. Invited commentary: more surprises from a gene desert. *Am J Epidemiol*. 2012; 175:488–91. [PubMed: 22350582]
27. Crowther-Swanepoel D, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. *Nat Genet*. 2010; 42:132–6. [PubMed: 20062064]
28. Enciso-Mora V, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). *Nat Genet*. 2010; 42:1126–30. [PubMed: 21037568]
29. Graham M, Adams JM. Chromosome 8 breakpoint far 3' of the c-myc oncogene in a Burkitt's lymphoma 2;8 variant translocation is equivalent to the murine pvt-1 locus. *Embo J*. 1986; 5:2845–51. [PubMed: 3024964]
30. Love C, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nat Genet*. 2012; 44:1321–5. [PubMed: 23143597]
31. Savage KJ, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood*. 2009; 114:3533–7. [PubMed: 19704118]
32. Pasqualucci L, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat Genet*. 2011; 43:830–7. [PubMed: 21804550]
33. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. *Science*. 1995; 270:1354–7. [PubMed: 7481822]
34. Novokhatska O, et al. Adaptor proteins intersectin 1 and 2 bind similar proline-rich ligands but are differentially recognized by SH2 domain-containing proteins. *PloS One*. 2013; 8:e70546. [PubMed: 23936226]
35. McGavin MK, et al. The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis. *J Exp Med*. 2001; 194:1777–87. [PubMed: 11748279]
36. Jia X, et al. Imputing amino acid polymorphisms in human leukocyte antigens. *PLoS One*. 2013; 8:e64683. [PubMed: 23762245]
37. Howell WM. HLA and disease: guilt by association. *Int J Immunogenet*. 2014; 41:1–12. [PubMed: 24004450]

38. Klitz W, Aldrich CL, Fildes N, Horning SJ, Begovich AB. Localization of predisposition to Hodgkin disease in the HLA class II region. *Am J Hum Genet.* 1994; 54:497–505. [PubMed: 8116619]
39. Price P, et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. *Immunol Rev.* 1999; 167:257–74. [PubMed: 10319267]
40. Kumar V, et al. Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility. *J Hum Genet.* 2011; 56:436–9. [PubMed: 21471979]
41. Yang J, et al. Common SNPs explain a large proportion of the heritability for human height. *Nat Genet.* 2010; 42:565–9. [PubMed: 20562875]
42. Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood.* 2007; 110:695–708. [PubMed: 17389762]
43. Turner JJ, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. *Blood.* 2010; 116:e90–8. [PubMed: 20699439]
44. Swerdlow, S.; Campo, E.; Harris, N. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press; Lyon, France: 2008.
45. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. *Genetics.* 2000; 155:945–59. [PubMed: 10835412]
46. Price AL, et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet.* 2006; 38:904–9. [PubMed: 16862161]
47. Schumacher FR, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. *Hum Mol Genet.* 2011; 20:3867–75. [PubMed: 21743057]
48. Siddiq A, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Hum Mol Genet.* 2012; 21:5373–84. [PubMed: 22976474]
49. Purcell S, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007; 81:559–75. [PubMed: 17701901]
50. Dixon AL, et al. A genome-wide association study of global gene expression. *Nat Genet.* 2007; 39:1202–7. [PubMed: 17873877]
51. Cheung VG, et al. Polymorphic cis- and trans-regulation of human gene expression. *PLoS Biol.* 2010; 8
52. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. *Am J Hum Genet.* 2011; 88:294–305. [PubMed: 21376301]
53. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet.* 2011; 88:76–82. [PubMed: 21167468]
54. Howlander, N., et al. SEER Cancer Statistics Review, 1975–2010. National Cancer Institute; Bethesda, MD: Apr. 2013 http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site
55. Fearnhead P. SequenceLDhot: detecting recombination hotspots. *Bioinformatics.* 2006; 22:3061–6. [PubMed: 17060358]
56. Fearnhead P, Harding RM, Schneider JA, Myers S, Donnelly P. Application of coalescent methods to reveal fine-scale rate variation and recombination hotspots. *Genetics.* 2004; 167:2067–81. [PubMed: 15342541]
57. Li N, Stephens M. Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. *Genetics.* 2003; 165:2213–33. [PubMed: 14704198]
58. Crawford DC, et al. Evidence for substantial fine-scale variation in recombination rates across the human genome. *Nat Genet.* 2004; 36:700–6. [PubMed: 15184900]
59. Luna A, Nicodemus KK. snp.plotter: an R-based SNP/haplotype association and linkage disequilibrium plotting package. *Bioinformatics.* 2007; 23:774–6. [PubMed: 17234637]








Figure 1. Association results, recombination hot-spots, and linkage disequilibrium (LD) plots for the regions newly associated with diffuse large B-cell lymphoma (DLBCL)

(a–d) Top, association results of GWAS data from stage 1 DLBCL-GWAS (grey diamonds) and combined data of stages 1–3 (red diamond) are shown in the top panels with $-\log_{10}(P)$ values (left y axis). Overlaid are the likelihood ratio statistics (right y axis) to estimate putative recombination hotspots across the region on the basis of 5 unique sets of 100 randomly selected control samples. Bottom, LD heatmap based on r^2 values from combined

control populations for all SNPs included in the GWAS. Shown are results for 6p25.3 (**a**), 8q24.21 (**b**), 2p23.36 (**c**), and p21.33 (**d**) regions.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1
Association of novel loci and new independent SNPs with risk of diffuse large B-cell lymphoma (DLBCL)

Location	Nearest gene(s)	SNP	Position ^a	Risk allele ^b	Other allele	RAF ^c	Stage	No. Cases/No. controls	OR	(95% CI)	P	P _{het}	I ²
6p25.3	<i>EXOC2</i>	rs116446171	484,453	G	C	0.019	Stage 1	2,661/6,220	2.26	(1.82–2.81)	1.48×10 ⁻¹³		
						0.018	Stage 2	1,194/1,443	2.70	(1.84–3.96)	3.99×10 ⁻⁷		
						0.019	Stage 3	1,351/4,460	1.78	(1.29–2.46)	0.00040		
							Combined	5,206/12,123	2.20	(1.87–2.59)	2.33×10⁻²¹	0.17	32.82
8q24.21	<i>PVT1</i>	rs13255292	129,076,573	T	C	0.321	Stage 1	2,661/6,221	1.19	(1.11–1.28)	1.25×10 ⁻⁶		
						0.315	Stage 2	1,195/1,444	1.30	(1.14–1.47)	4.29×10 ⁻⁵		
						0.330	Stage 3	1,322/4,498	1.22	(1.09–1.36)	0.001		
							Combined	5,178/12,163	1.22	(1.15–1.29)	9.98×10⁻¹³	0.37	8.30
		rs4733601	129,269,466	A	G	0.477	Stage 1	2,661/6,221	1.19	(1.11–1.27)	4.22×10 ⁻⁷		
						0.479	Stage 2	1,196/1,445	1.19	(1.05–1.33)	0.004		
						0.487	Stage 3	1,337/4,523	1.19	(1.07–1.32)	0.0016		
							Combined	5,194/12,189	1.18	(1.11–1.25)	3.63×10⁻¹¹	0.09	43.85
6p21.33	<i>HLA-B</i>	rs2523607	31,322,790	A	T	0.120	Stage 1	2,661/6,221	1.45	(1.29–1.64)	7.10×10 ⁻¹⁰		
						0.123	Stage 2	1,195/1,444	1.14	(0.96–1.35)	0.14		
						0.109	Stage 3 ^d	1,114/1,102	1.25	(1.04–1.51)	0.019		
							Combined	4,970/8767	1.32	(1.21–1.44)	2.40×10⁻¹⁰	0.26	21.63
2p23.3	<i>NCOA1</i>	rs79480871	24694472	T	C	0.076	Stage 1	2,660/6,220	1.35	(1.17–1.55)	3.51×10 ⁻⁵		
						0.057	Stage 2	1,195/1,443	1.56	(1.22–1.99)	0.00037		
						0.063	Stage 3	1,344/4,524	1.19	(0.98–1.46)	0.084		
							Combined	5,199/12,187	1.34	(1.21–1.49)	4.23×10⁻⁸	0.15	34.59

^a Position according to human reference NCBI37/hg19;

^b Allele associated with an increased risk of DLBCL;

^c Risk allele frequency in controls;

^d Not genotyped in NCI Replication study.